🟢 Immunic is trading 5% up today after surpassing second-quarter expectations

Immunic is trading 5.32% up now at $14.85 after reporting second-quarter results that surpassed Wall Street expectations.

• Reported an $0.80 loss per share versus the $1.24 estimate.
• Management reaffirmed Phase 3 ENSURE trial data remain on track for year-end 2026.
• Its $155.1 million cash balance should fund operations into late 2027.